Physician profile
Patrick L Keating
NPI 1679864292
$7,364.98
in general payments reported to CMS, 2019-2025
28 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,067 · 2020: $514 · 2021: $752 · 2022: $812 · 2023: $1,204 · 2024: $1,924 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336 · Travel and Lodging: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.50 |
| Travel and Lodging | $885.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,370.32 | 2019-2025 | Clareon, Centurion, Argos |
| Abbvie INC. | $698.98 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $645.68 | 2019-2025 | Cequa |
| Allergan, INC. | $560.86 | 2019-2022 | |
| Oyster Point Pharma, INC. | $449.41 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $349.56 | 2019-2025 | |
| Glaukos Corporation | $269.85 | 2020-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Idose |
| Novartis Pharmaceuticals Corporation | $222.97 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $211.83 | 2023-2025 | Xiidra, Miebo, Infuse |
| Ivantis, INC | $183.98 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $179.48 | 2020-2023 | Acthar |
| Johnson & Johnson Surgical Vision, INC. | $168.01 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $163.66 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $158.22 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $123.42 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $91.44 | 2025 | Oxervate |
| Sight Sciences, INC. | $72.82 | 2020-2021 | |
| Harrow Eye, LLC | $67.99 | 2024-2025 | Vevye |
| Carl Zeiss Meditec USA, INC. | $60.84 | 2021 | |
| Shire North American Group INC | $56.98 | 2019 | |
| Lkc Technologies, INC. | $56.44 | 2023 | |
| Optos, INC. | $46.03 | 2019 | |
| Eyevance Pharmaceuticals LLC | $44.76 | 2020-2022 | |
| Horizon Therapeutics Plc | $34.06 | 2022-2023 | Tepezza |
| Omeros Corporation | $32.50 | 2019 | |
| Amgen INC. | $18.85 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $14.55 | 2022 | |
| New World Medical,INC. | $11.49 | 2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Via360 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Keating listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.